Last reviewed · How we verify

Placebo of N-acetylcysteine

University Hospital, Lille · Phase 3 active Small molecule

Placebo of N-acetylcysteine is a Small molecule drug developed by University Hospital, Lille. It is currently in Phase 3 development.

This is a placebo control arm with no active pharmacological mechanism.

At a glance

Generic namePlacebo of N-acetylcysteine
SponsorUniversity Hospital, Lille
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo of N-acetylcysteine, this formulation contains no active drug and serves as a control comparator in clinical trials. N-acetylcysteine itself is a mucolytic and antioxidant agent, but the placebo arm is inert and used to assess the true efficacy of the active drug through comparison.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo of N-acetylcysteine

What is Placebo of N-acetylcysteine?

Placebo of N-acetylcysteine is a Small molecule drug developed by University Hospital, Lille.

How does Placebo of N-acetylcysteine work?

This is a placebo control arm with no active pharmacological mechanism.

Who makes Placebo of N-acetylcysteine?

Placebo of N-acetylcysteine is developed by University Hospital, Lille (see full University Hospital, Lille pipeline at /company/university-hospital-lille).

What development phase is Placebo of N-acetylcysteine in?

Placebo of N-acetylcysteine is in Phase 3.

Related